Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALC Alcon	$89.01 +0.8%	$89.62	$80.48 ▼ $101.10	$43.54B	0.95	1.19 million shs	1.02 million shs
HLN Haleon	$10.35 -0.2%	$10.72	$8.25 ▼ $11.42	$46.61B	0.25	9.42 million shs	17.83 million shs
LZAGY Lonza Group	$71.16 -0.3%	$69.47	$53.48 ▼ $73.29	$51.54B	1.16	73,447 shs	68,657 shs
MRNA Moderna	$28.69 +4.0%	$26.52	$23.15 ▼ $129.39	$10.67B	1.85	8.63 million shs	14.53 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALC Alcon	+0.42%	+3.46%	+2.85%	-4.66%	-0.88%
HLN Haleon	-0.24%	-1.15%	-8.80%	+1.82%	+25.42%
LZAGY Lonza Group	+1.45%	+2.72%	+3.23%	+16.89%	+30.94%
MRNA Moderna	+1.58%	+7.48%	+3.88%	+1.58%	-76.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALC Alcon	1.8021 of 5 stars	2.4	3.0	0.8	0.0	1.3	0.8	1.3
HLN Haleon	2.1716 of 5 stars	2.4	3.0	2.5	0.0	1.9	0.0	1.3
LZAGY Lonza Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	4.3657 of 5 stars	4.0	2.0	0.0	4.6	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALC Alcon	2.80	Moderate Buy	$106.13	19.23% Upside
HLN Haleon	2.73	Moderate Buy	$12.33	19.08% Upside
LZAGY Lonza Group	4.00	Strong Buy	N/A	N/A
MRNA Moderna	2.04	Hold	$46.61	62.46% Upside

Current Analyst Ratings Breakdown

Latest LZAGY, MRNA, ALC, and HLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/27/2025	HLN Haleon	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	HLN Haleon	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$13.40
5/22/2025	ALC Alcon	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/20/2025	ALC Alcon	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/14/2025	ALC Alcon	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$102.00 ➝ $99.00
5/14/2025	ALC Alcon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $110.00
5/9/2025	HLN Haleon	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$11.25
5/6/2025	HLN Haleon	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/2/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $70.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALC Alcon	$9.91B	4.43	$5.60 per share	15.89	$43.70 per share	2.04
HLN Haleon	$14.35B	3.24	$0.50 per share	20.80	$4.58 per share	2.26
LZAGY Lonza Group	$7.47B	6.88	$2.00 per share	35.62	$14.76 per share	4.82
MRNA Moderna	$3.24B	3.43	N/A	N/A	$28.33 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALC Alcon	$1.02B	$2.25	39.56	27.05	2.26	11.28%	6.95%	4.92%	8/19/2025 (Estimated)
HLN Haleon	$1.84B	$0.39	26.54	21.12	2.95	12.86%	17.65%	8.58%	7/2/2025 (Estimated)
LZAGY Lonza Group	$722.43M	N/A	0.00	32.79	2.38	N/A	N/A	N/A	7/23/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)

Latest LZAGY, MRNA, ALC, and HLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	ALC Alcon	$0.77	$0.73	-$0.04	$0.70	$2.52 billion	$2.33 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALC Alcon	N/A	N/A	N/A	N/A	4 Years
HLN Haleon	$0.25	2.42%	N/A	64.10%	N/A
LZAGY Lonza Group	$0.11	0.15%	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest LZAGY, MRNA, ALC, and HLN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/10/2025	LZAGY Lonza Group		$0.1054	0.15%	5/14/2025	5/15/2025	5/30/2025
4/7/2025	ALC Alcon	annual	$0.3270	0.3%	5/14/2025	5/14/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALC Alcon	0.21	2.70	1.66
HLN Haleon	0.53	0.98	0.78
LZAGY Lonza Group	0.45	1.52	1.04
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALC Alcon	53.86%
HLN Haleon	6.67%
LZAGY Lonza Group	0.04%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ALC Alcon	N/A
HLN Haleon	N/A
LZAGY Lonza Group	0.07%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALC Alcon	25,599	493.24 million	N/A	Optionable
HLN Haleon	24,561	4.49 billion	N/A	Not Optionable
LZAGY Lonza Group	18,000	722.26 million	721.76 million	Not Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

LZAGY, MRNA, ALC, and HLN Headlines

Recent News About These Companies

Moderna flu shot outperforms marketed vaccines in pivotal late-stage trial

July 1 at 1:04 PM | thesiliconreview.comT

Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot

July 1 at 1:04 PM | biospace.comB

Moderna’s New Flu Shot Shows Strong Results in Older Adults

July 1 at 1:04 PM | usnews.com

Moderna Stock Gains on Encouraging Flu Vaccine Data

July 1 at 10:20 AM | zacks.com

The U.S. must invest in mRNA vaccines against pandemic influenza viruses now

July 1 at 8:03 AM | statnews.comS

Moderna flu vaccine shows superior results in phase 3 study

July 1 at 8:03 AM | pharmatimes.comP

13,644 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Diversified Trust Co

July 1 at 4:26 AM | marketbeat.com

Spire Wealth Management Sells 17,807 Shares of Moderna, Inc. (NASDAQ:MRNA)

July 1 at 3:55 AM | marketbeat.com

Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more

July 1 at 3:02 AM | statnews.comS

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages

July 1 at 2:47 AM | marketbeat.com

Moderna flu vaccine trial results clear path for combo shot

June 30 at 10:01 PM | beckershospitalreview.comB

Moderna shines spotlight on new flu vaccine data

June 30 at 5:01 PM | pharmaphorum.comP

Moderna’s flu vaccine hits goal, paving way for combo shot

June 30 at 5:01 PM | bostonglobe.comB

Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA

June 30 at 5:01 PM | fiercebiotech.comF

Moderna’s mRNA flu shot outperforms current standard at Phase III

June 30 at 5:01 PM | finance.yahoo.com

Moderna flu shot outperforms marketed vaccines in large late-stage trial

June 30 at 5:01 PM | biopharmadive.comB

Experimental Moderna flu shot more effective than approved vaccine, company says

June 30 at 5:01 PM | msn.com

Moderna announces promising efficacy results from mRNA flu vaccine trial

June 30 at 5:01 PM | cidrap.umn.eduC

Moderna Stock Is Climbing on Trial Data. A Flu-Covid Vaccine Isn’t a Sure Thing.

June 30 at 5:01 PM | msn.com

Moderna, Inc. (MRNA) Opinions on Positive Flu Vaccine Trial Results

June 30 at 1:56 PM | quiverquant.comQ

Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More

June 30 at 12:00 PM | investopedia.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SoundHound’s AI Growth Story Is Just Getting Started
By Gabriel Osorio-Mazilli | June 16, 2025
View SoundHound’s AI Growth Story Is Just Getting Started
Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects
By Sam Quirke | June 10, 2025
View Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
Qualcomm: A Technical Deep-Dive Confirms the Worst
By Sam Quirke | June 3, 2025
View Qualcomm: A Technical Deep-Dive Confirms the Worst
Qualcomm: A Technical Setup Is Emerging, and It's Bullish
By Sam Quirke | June 18, 2025
View Qualcomm: A Technical Setup Is Emerging, and It's Bullish

LZAGY, MRNA, ALC, and HLN Company Descriptions

Alcon NYSE:ALC

$89.01 +0.73 (+0.83%)

Closing price 03:59 PM Eastern

Extended Trading

$89.06 +0.05 (+0.06%)

As of 06:58 PM Eastern

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Haleon NYSE:HLN

$10.35 -0.02 (-0.19%)

Closing price 03:59 PM Eastern

Extended Trading

$10.42 +0.08 (+0.72%)

As of 07:31 PM Eastern

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Lonza Group OTCMKTS:LZAGY

$71.16 -0.20 (-0.28%)

As of 03:59 PM Eastern

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Moderna NASDAQ:MRNA

$28.69 +1.10 (+3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$28.80 +0.11 (+0.39%)

As of 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time